The Use of Cannabis in Psychopharmacology
Presented by Christopher Rossilli Psy.D, MSCP, ABMP
Friday, March 15th, 2024
8:10-9:10am PT / 10:10-11:10am CT / 11:10am-12:10pm ET
Event held online via Zoom
This continuing education course is designed to offer knowledge on the underlying importance of medical cannabis and how it can be integrated into clinical practice as medical cannabis legalization gains momentum throughout the United States and dispensaries open throughout the nation. Morevover, as more states pass medical cannabis legislation, it is important to understand the pharmacology of cannabis, CBD, and various formulations that can affect psychotropic medications and influence medical conditions. This course is not meant to be exhaustive, as numerous strains can be of benefit or interest to populations that psychologists treat. Additionally, there are master’s degrees in medical cannabis, so this subject has a great breadth. Additionally, the course is meant to provide essential details on the significance of medical marijuana and how understanding its pharmacology, history/legal process, and clinical integration can help position psychologists to one day gain prescriptive authority for cannabis privileges and improve patient care.
When attended in full, this program offers 1.0 APA CEs for Psychologists.
This continuing education course is designed to offer knowledge on the underlying importance of medical cannabis and how it can be integrated into clinical practice as medical cannabis legalization gains momentum throughout the United States and dispensaries open throughout the nation. Morevover, as more states pass medical cannabis legislation, it is important to understand the pharmacology of cannabis, CBD, and various formulations that can affect psychotropic medications and influence medical conditions. This course is not meant to be exhaustive, as numerous strains can be of benefit or interest to populations that psychologists treat. Additionally, there are master’s degrees in medical cannabis, so this subject has a great breadth. Additionally, the course is meant to provide essential details on the significance of medical marijuana and how understanding its pharmacology, history/legal process, and clinical integration can help position psychologists to one day gain prescriptive authority for cannabis privileges and improve patient care.
After attending this intermediate-level program, participants will be able to:
- Discuss the significance of medical marijuana and its connection to pharmacology.
- Identify the clinical integrations of cannabis for psychologists.
This program meets APA’s continuing education STANDARD 1.1: Program content focuses on application of psychological assessment and/or intervention methods that have overall consistent and credible empirical support in the contemporary peer reviewed scientific literature beyond those publications and other types of communications devoted primarily to the promotion of the approach.
This program meets APA’s continuing education GOAL 3: Program will allow psychologists to maintain, develop, and increase competencies in order to improve services to the public and enhance contributions to the profession.
Christopher Rossilli, Psy.D, MSCP, ABMP
Christopher Rossilli, PsyD, MSCP, ABMP, is a board-certified medical psychologist with the American Board of Medical Psychology and passed the PEP exam in 2018. Dr. Rossilli an Albizu University (PsyD) and Nova Southeastern University (MSCP) graduate. He completed two RXP practicums with neurology and primary care. He currently operates a private practice located in Fleming Island, Florida. His research interests include brain health, medical cannabis, and ketamine. For the past seven years, Dr. Rossilli has chaired the Medical Psychology division of the Florida Psychological Association and has served as an LAPPB Delegate and Florida RXP committee member. He is an adjunct facility member at the Chicago School MSCP program that teaches pathophysiology. He has presented on various subject matters, such as post-stroke delirium, over-the-counter medication reviews, and medical marijuana.
Hill, K. P., Gold, M. S., Nemeroff, C. B., McDonald, W., Grzenda, A., Widge, A. S., Rodriguez, C., Kraguljac, N. V., Krystal, J. H., & Carpenter, L. L. (2022). Risks and Benefits of Cannabis and Cannabinoids in Psychiatry. American Journal of Psychiatry, 179(2), 98–109. https://doi.org/10.1176/appi.ajp.2021.21030320
Haney, M. (2022). Cannabis Use and the Endocannabinoid System: A Clinical Perspective. American Journal of Psychiatry, 179(1), 21–25. https://doi.org/10.1176/appi.ajp.2021.211111383
Stanciu, C. N., Brunette, M. F., Teja, N., & Budney, A. J. (2021). Evidence for Use of Cannabinoids in Mood Disorders, Anxiety Disorders, and PTSD: A Systematic Review. Psychiatric Services, 72(4), appi.ps.2020001. https://doi.org/10.1176/appi.ps.202000189
Target Audience: Psychologists, social workers, other mental health care providers.
Psychologists. This program, when attended in its entirety, is available for 1.0 continuing education credits. The Chicago School of Professional Psychology is committed to accessibility and non-discrimination in its continuing education activities. The Chicago School of Professional Psychology is also committed to conducting all activities in conformity with the American Psychological Association’s Ethical Principles for Psychologists. Participants are asked to be aware of the need for privacy and confidentiality throughout the program. If program content becomes stressful, participants are encouraged to process these feelings during discussion periods.
Non Psychologists. Most licensing boards accept Continuing Education Credits sponsored by the American Psychological Association but non-psychologists are recommended to consult with their specific state-licensing board to ensure that APA-sponsored CE is acceptable.
*Participants must attend 100% of the program in order to obtain a Certificate of Attendance.
If participants have special needs, we will attempt to accommodate them. Please address questions, concerns and any complaints to [email protected]. There is no commercial support for this program nor are there any relationships between the CE Sponsor, presenting organization, presenter, program content, research, grants, or other funding that could reasonably be construed as conflicts of interest.